These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 19087149

  • 1. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
    Hesse D, Frederiksen JL, Koch-Henriksen N, Schreiber K, Stenager E, Heltberg A, Ravnborg M, Bendtzen K, Sellebjerg F, Sorensen PS.
    Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
    [Abstract] [Full Text] [Related]

  • 2. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [Abstract] [Full Text] [Related]

  • 3. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic.
    Zarkou S, Carter JL, Wellik KE, Demaerschalk BM, Wingerchuk DM.
    Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436
    [Abstract] [Full Text] [Related]

  • 4. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D, Sellebjerg F, Sorensen PS.
    Neurology; 2009 Aug 04; 73(5):372-7. PubMed ID: 19652141
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.
    Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE, Koch-Henriksen N, Svejgaard A, Soelberg Sørensen P.
    Eur J Neurol; 2009 Dec 04; 16(12):1291-8. PubMed ID: 19558503
    [Abstract] [Full Text] [Related]

  • 7. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.
    Mult Scler; 2014 Apr 04; 20(5):577-87. PubMed ID: 24009164
    [Abstract] [Full Text] [Related]

  • 8. Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent.
    Sominanda A, Hillert J, Fogdell-Hahn A.
    Eur J Neurol; 2009 Jan 04; 16(1):21-6. PubMed ID: 18727672
    [Abstract] [Full Text] [Related]

  • 9. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, Bertolotto A, Polman CH, Killestein J.
    Mult Scler; 2009 Feb 04; 15(2):212-8. PubMed ID: 18805837
    [Abstract] [Full Text] [Related]

  • 10. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 11. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [Abstract] [Full Text] [Related]

  • 12. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group.
    Neurology; 2005 Jul 12; 65(1):33-9. PubMed ID: 15888603
    [Abstract] [Full Text] [Related]

  • 13. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D.
    Brain; 2004 Feb 12; 127(Pt 2):259-68. PubMed ID: 14607790
    [Abstract] [Full Text] [Related]

  • 14. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR, Cadavid D, Wolansky L, Skurnick J.
    Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
    [Abstract] [Full Text] [Related]

  • 15. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Millonig A, Rudzki D, Hölzl M, Ehling R, Gneiss C, Künz B, Berger T, Reindl M, Deisenhammer F.
    Mult Scler; 2009 Aug 03; 15(8):977-83. PubMed ID: 19465447
    [Abstract] [Full Text] [Related]

  • 16. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 03; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT investigators.
    Neurology; 2009 Nov 03; 73(18):1493-500. PubMed ID: 19884577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.